Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Back to dashboard
Company Information
About this company
Key people
William M. Greenman
Executive Chairman of the board
Jami Dover Nachtsheim
Independent Director
Vivek K. Jayaraman
President, Chief Executive Officer, Director
Kevin Dennis Green
Chief Financial Officer
Chrystal N. Jensen
Chief Legal Office, General Counsel and Secretary
Richard J. Benjamin
Chief Medical Officer
Frank R. Witney
Lead Independent Director
Eric H. Bjerkholt
Independent Director
Dean A. Gregory
Independent Director
Ann Lucena
Independent Director
Click to see more
Key facts
- Shares in issue200.37m
- EPICCERS
- ISINUS1570851014
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$605.11m
- Employees275
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.